Literature DB >> 8739837

Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion.

R Granata1, G K Wenning, J Jolkkonen, P Jenner, C D Marsden.   

Abstract

Striatal mRNA expression for preproenkephalin (PPE) and preprotachykinin (PPT) was studied in unilateral 6-OHDA lesioned rats treated subchronically with a range of selective and non-selective D-1 or D-2 dopamine (DA) agonists. Apomorphine (5 mg/kg sc), pergolide (0.5 mg/kg sc), SKF 38393 (5 mg/kg sc), SKF 80723 (1.5 mg/kg sc), and quinpirole (5 mg/kg sc), or 0.9% saline (150 microliters sc) were all given twice daily (except pergolide: once daily) for 7 days. The abundance of PPE mRNA was not altered by any of these DA agonists in the intact striatum contralateral to the 6-OHDA lesion. Only apomorphine and quinpirole increased the abundance of PPT mRNA in the intact striatum. In saline treated 6-OHDA lesioned animals PPE mRNA was elevated (+160%, p < 0.005) and PPT mRNA decreased (-36%, p < 0.005) in the denervated striatum. The up-regulation of striatal PPE mRNA in the lesioned striatum was reversed only by pergolide. The downregulation of striatal PPT mRNA in the lesioned striatum was reversed only by apomorphine. The differential sensitivity of the striatal PPE message to the long-acting DA agonist pergolide, and of the striatal PPT message to the mixed D-1/D-2 DA agonist apomorphine suggests that the striatopallidal enkephalinergic pathways are mainly regulated by prolonged DA receptor stimulation, whereas the striatonigral substance P pathways are mainly regulated by mixed D-1/D-2 DA receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739837     DOI: 10.1007/BF01271237

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  47 in total

1.  Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions.

Authors:  P Voorn; G Roest; H J Groenewegen
Journal:  Brain Res       Date:  1987-06-02       Impact factor: 3.252

2.  Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.

Authors:  S A Factor; J R Sanchez-Ramos; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-04       Impact factor: 10.154

3.  Local cerebral metabolic effects induced by nigral stimulation following ventromedial thalamic lesions. I: Basal ganglia and related motor structures.

Authors:  H E Savaki; J A Girault; M Desban; J Glowinski; M J Besson
Journal:  Brain Res Bull       Date:  1984-06       Impact factor: 4.077

4.  The cells of origin of nigrotectal, nigrothalamic and nigrostriatal projections in the rat.

Authors:  R L Faull; W R Mehler
Journal:  Neuroscience       Date:  1978       Impact factor: 3.590

Review 5.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

6.  Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.

Authors:  J F Chen; V J Aloyo; B Weiss
Journal:  Neuroscience       Date:  1993-06       Impact factor: 3.590

7.  Dopamine receptor gene expression by enkephalin neurons in rat forebrain.

Authors:  C Le Moine; E Normand; A F Guitteny; B Fouque; R Teoule; B Bloch
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

8.  Involvement of dopamine D1 and D2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain.

Authors:  J A Angulo
Journal:  J Neurochem       Date:  1992-03       Impact factor: 5.372

9.  Interaction of pergolide with central dopaminergic receptors.

Authors:  M Goldstein; A Lieberman; J Y Lew; T Asano; M R Rosenfeld; M H Makman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

10.  Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.

Authors:  K K Gnanalingham; D D Erol; A J Hunter; L A Smith; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

View more
  2 in total

Review 1.  Target identification for CNS diseases by transcriptional profiling.

Authors:  C Anthony Altar; Marquis P Vawter; Stephen D Ginsberg
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

Review 2.  Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.

Authors:  Abdeslam Chagraoui; Giuseppe Di Giovanni; Philippe De Deurwaerdère
Journal:  Biomolecules       Date:  2022-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.